Even though invasive lobular carcinoma (ILC) accounts for 10-15% of the breast cancer seen in the US, there remains much to be learned about the unique nature of this disease. For example, patients with ILC are likely to have tumors with expression of estrogen receptor alpha (ER), a biomarker of good prognosis. Yet, patients with ER+ ILC have worse long-term outcomes compared to patients with the more commonly studied subtype of ER+ invasive ductal carcinoma (IDC). The standard treatment regimen for ER+ disease includes endocrine therapy, so the big picture focus of this grant asks: why do some ILC patients have a worse outcome than expected on endocrine therapy, and for those patients, what additional treatments can we provide? This grant aims to assess the effect of FGFR4 expression on cell survival and signaling in vitro, identify biomarkers for FGFR4 activation in silico, and test the efficacy of FGFR4 inhibition on clinical samples ex vivo. Methods include 1) FGFR4 inhibition with shRNAs and small-molecule inhibitors, 2) RNA-Sequencing, 3) machine-learning, and 4) explant models of ILC patient tumors. The ultimate goal of the proposed aims is to provide rationale for specific combination targeted therapy in patients with lobular breast cancer, in accordance with the mission statement of the NCI.

Public Health Relevance

The goal of this research is to identify why endocrine therapy has lasting benefits for only a subset of women with breast cancer. The proposed studies include RNA-Sequencing to understand how molecular changes impact survival outcomes. Results of this and future research will complement findings from ongoing clinical trials to identify the best combination of targeted therapy for each individual with breast cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Hopkins, Barbara L; Nadler, Monica; Skoko, John J et al. (2018) A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7. Antioxid Redox Signal 28:62-77
Tasdemir, Nilgun; Bossart, Emily A; Li, Zheqi et al. (2018) Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res 78:6209-6222
Nagle, Alison M; Levine, Kevin M; Tasdemir, Nilgun et al. (2018) Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res 24:5165-5177
Du, Tian; Zhu, Li; Levine, Kevin M et al. (2018) Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep 8:7205
Du, Tian; Sikora, Matthew J; Levine, Kevin M et al. (2018) Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 20:106
Li, Zheqi; Levine, Kevin M; Bahreini, Amir et al. (2018) Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. Endocrinology 159:285-296
Bahreini, Amir; Li, Zheqi; Wang, Peilu et al. (2017) Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res 19:60
Chen, Lin; Vasilatos, Shauna N; Qin, Ye et al. (2017) Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget 8:81737-81753